CoChat

Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects

Prueksaritanont, Thomayant, Vega, José M., Zhao, Jamie, Gagliano, Kathleen, Kuznetsova, Olga, Musser, Bret, Amin, Raju D., Liu, Lida, Roadcap, Brad A., Dilzer, Stacy, Lasseter, K. C., Rogers, J. Douglas · 2001 · The Journal of Clinical Pharmacology
Cited by 55

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Two randomized, two‐period crossover studies were conducted to evaluate the effects of repeat oral dosing of troglitazone (Study I) and pioglitazone (Study II) on the pharmacokinetics of plasma HMG‐CoA reductase inhibitors following multiple oral doses of simvastatin and of simvastatin on the plasma pharmacokinetics of troglitazone (Study I) in healthy subjects. In both studies, each subject received two treatments. Treatment A consisted of once‐daily oral doses of troglitazone 400 mg (Study I) or pioglitazone 45 mg (Study II) for 24 days with coadministration of once‐daily doses of simvastatin 40 mg (Study I) or 80 mg (Study II) on Days 15 through 24. Treatment B consisted of once‐daily oral doses of simvastatin 40 mg (Study I) or 80 mg (Study II) for 10 days. In Study I, the area under the plasma concentration‐time profiles (AUC) and maximum plasma concentrations (C max) of HMG‐CoA reductase inhibitors in subjects who received both troglitazone and simvastatin were decreased modestly (by ∼30% for C max and ∼40% for AUC), but time to reach C max(t max) did not change, as compared with those who received simvastatin alone. Simvastatin, administered orally as a 40 mg tablet daily for 10 days, did not affect the AUC or t max (p > 0.5) but caused a small but clinically insignificant increase (∼25%) in C max for troglitazone. In Study II, pioglitazone, at the highest approved dose for clinical use, did not significantly alter any of the pharmacokinetic parameters (AUC, C max, and t max) of simvastatin HMG‐CoA reductase inhibitory activity. For all treatment regimens, side effects were mild and transient, suggesting that coadministration of simvastatin with either troglitazone or pioglitazone was well tolerated. The modest effect of troglitazone on simvastatin pharmacokinetics is in agreement with the suggestion that troglitazone is an inducer of CYP3A. The insignificant effect of simvastatin on troglitazone pharmacokinetics is consistent with the conclusion that simvastatin is not a significant inhibitor for drug‐metabolizing enzymes. The lack of pharmacokinetic effect of pioglitazone on simvastatin supports the expectation that this combination may be used safely.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/00912700122010311

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 55

Metadata

Authors
Prueksaritanont, T., Vega, J. M., Zhao, J., Gagliano, K., Kuznetsova, O., Musser, B., Amin, R. D., Liu, L., Roadcap, B. A., Dilzer, S., Lasseter, K. C., & Rogers, J. D.
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2001-05
Volume
41
Issue
5
Pages
573-581
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
OpenAlex
W2122599308
Cited by
55
References
1
FWCI
3.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects. https://app.cochat.ai/papers/10.1177/00912700122010311
The paper
Prueksaritanont, T., Vega, J. M., Zhao, J., Gagliano, K., Kuznetsova, O., Musser, B., Amin, R. D., Liu, L., Roadcap, B. A., Dilzer, S., Lasseter, K. C., & Rogers, J. D. (2001). Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects. The Journal of Clinical Pharmacology. https://doi.org/10.1177/00912700122010311

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.